Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...

The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...

Despite falling Eylea sales, Regeneron Pharmaceuticals once again beats Wall Street expectations Regeneron's revenue was about $3.79 billion in the fourth quarter of 2024, up 10.5% year-on-year ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...